IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages 344-356

  Fujisawa, Toshio ^a   Joshi, Bharat H ^a   Puri, Raj K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

ERK1 2; IL 13R 2; matrix metalloproteinase; Metastasis; Ovarian cancer

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA2; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEINASE; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861602528     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26366     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Roett MA, Evans P,. Ovarian cancer: an overview. Am Fam Physician 2009; 80: 609-16.
3. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK,. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 2006; 107: 1407-18.
4. Fujisawa T, Nakashima H, Nakajima A, Joshi BH, Puri RK,. Targeting IL-13Ralpha2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. Int J Cancer 2011; 128: 1221-31.
5. Joshi BH, Puri RK,. Tumor immunology. Curr Mol Med 2009; 9: 665-6.
6. Joshi BH, Puri RK,. IL-13 receptor-alpha2: a novel target for cancer therapy. Immunotherapy 2009; 1: 321-7.
7. Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK,. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin Cancer Res 2010; 16: 577-86.
8. Chiaramonte MG, Mentink-Kane M, Jacobson BA, Cheever AW, Whitters MJ, Goad ME, Wong A, Collins M, Donaldson DD, Grusby MJ, Wynn TA,. Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med 2003; 197: 687-701.
9. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A,. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12: 99-106.
10. Kawakami K, Taguchi J, Murata T, Puri RK,. The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001; 97: 2673-9.
11. Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ,. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res 2002; 62: 1103-9.
12. Fujisawa T, Joshi B, Nakajima A, Puri RK,. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res 2009; 69: 8678-85.
13. Benbow U, Brinckerhoff CE,. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 1997; 15: 519-26.
14. Westermarck J, Kahari VM,. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781-92.
15. Fu H, Hu Z, Wen J, Wang K, Liu Y,. TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 648-56.
16. Li LH, Zheng MH, Luo Q, Ye Q, Feng B, Lu AG, Wang ML, Chen XH, Su LP, Liu BY,. P21-activated protein kinase 1 induces colorectal cancer metastasis involving ERK activation and phosphorylation of FAK at Ser-910. Int J Oncol 2010; 37: 951-62.
17. Ming J, Liu N, Gu Y, Qiu X, Wang EH,. PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer. Pathology 2009; 41: 118-26.
18. Kawakami K, Terabe M, Kawakami M, Berzofsky JA, Puri RK,. Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain. Cancer Res 2006; 66: 4434-42.
19. Murata T, Obiri NI, Debinski W, Puri RK,. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 1997; 238: 90-4.
20. Joshi BH, Leland P, Calvo A, Green JE, Puri RK,. Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy. Cancer Res 2008; 68: 9311-7.
21. Joshi BH, Plautz GE, Puri RK,. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 2000; 60: 1168-72.
22. Puri S, Joshi BH, Sarkar C, Mahapatra AK, Hussain E, Sinha S,. Expression and structure of interleukin 4 receptors in primary meningeal tumors. Cancer 2005; 103: 2132-42.
23. Jones LJ, Upson RH, Haugland RP, Panchuk-Voloshina N, Zhou M,. Quenched BODIPY dye-labeled casein substrates for the assay of protease activity by direct fluorescence measurement. Anal Biochem 1997; 251: 144-52.
24. Joshi BH, Puri RK,. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. Protein Expr Purif 2005; 39: 189-98.
25. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J,. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-24.
26. Whitmarsh AJ, Davis RJ,. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 1996; 74: 589-607.
27. Lewis TS, Shapiro PS, Ahn NG,. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49-139.
28. Murata T, Obiri NI, Puri RK,. Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction. Int J Cancer 1997; 70: 230-40.
29. de Vries JE,. Molecular and biological characteristics of interleukin-13. Chem Immunol 1996; 63: 204-18.
30. Hershey GK,. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003; 111: 677-90; quiz 91.
31. Gessner A, Mohrs K, Mohrs M,. Mast cells, basophils, and eosinophils acquire constitutive IL-4 and IL-13 transcripts during lineage differentiation that are sufficient for rapid cytokine production. J Immunol 2005; 174: 1063-72.
32. Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK,. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitam Horm 2006; 74: 479-504.
33. Rodriguez A, Macewan SR, Meyerson H, Kirk JT, Anderson JM,. The foreign body reaction in T-cell-deficient mice. J Biomed Mater Res A 2009; 90: 106-13.
34. Nakashima H, Fujisawa T, Husain SR, Puri RK,. Interleukin-13 receptor alpha2 DNA prime boost vaccine induces tumor immunity in murine tumor models. J Transl Med 2010; 8: 116.
35. Kawakami K, Terabe M, Kioi M, Berzofsky JA, Puri RK,. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors. Clin Cancer Res 2006; 12: 4678-86.